Stocktoria
HUTCHMED (China) Ltd HCM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-05-19
HUTCHMED (China) Ltd statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -7.1% | -6.9% | 2.2% | -95.6% | -92.2% |
| Net margin | 83.3% | 6.0% | 12.0% | -84.6% | -54.7% |
| FCF margin | -14.4% | -2.8% | 22.3% | -71.6% | -62.0% |
| Return on assets | 26.1% | 3.0% | 7.9% | -35.1% | -14.2% |
| Return on equity | 36.5% | 4.9% | 13.6% | -56.7% | -18.7% |
| Debt / equity | 0.07× | 0.11× | 0.11× | 0.03× | — |
| Current ratio | 4.96 | 2.83 | 2.72 | 2.37 | 3.89 |
| Revenue growth | -13.0% | -24.8% | 96.5% | 19.7% | 56.2% |
Source: SEC EDGAR filings · CIK 0001648257 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.